All News
ACR23 – Day 1 Report
ACR 2023 is back in San Diego for its annual convergence of thousands of rheumatologists to partake, discover and learn from thousands of abstracts and hundreds of sessions and presentations. It was a big return for the Poster Hall with rows and rows of research, friends, fellows and poster tours. Below are a few of my favorite presentations from the posters, Plenary and oral sessions on day one.
Read Article
Canadian Consensus on MSK Ultrasound
Dr. Jack Cush discusses abstract 0726 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Read Article
#ACR23 @RheumNow #GreatDebate
Treatment for PMR by Spiera
- Plan rapid GC taper. It is OK to flare, prepare pt!
- Low threshold to introduce anti-IL-6 for GC intolerance or AEs
No need for initial biologic treatment for PMR/GCA
@philseo rebuttal upcoming... https://t.co/A0f3b0fMOr
Eric Dein ( View Tweet)
Should IL-6i be first line in GCA/PMR? Dr. Spiera says steroids work, are cheap; no evidence of using IL6i early in disease. there had been cases where pts still had active vasculitis while on IL-6i. He starts with steroids first then add IL6i #GreatDebate #ACR23 @rheumnow https://t.co/Oq5Q9HFtW3
TheDaoIndex KDAO2011 ( View Tweet)
#ACR23 #Debate Dr Spiera says NO need to up front use #glucocorticoid #sparing drugs in PMR - maybe only if flaring. Esp in PMR vs #GCA where maybe bDMARD in GCA in some Pts (my opinion) but for sure if failing #ACRbest #ACR23 @RheumNow @ACRheum https://t.co/Rt7rGZv3fW
Janet Pope ( View Tweet)
ACR#23 Abs #1023: IgG4-RD males > likely (vs females) to have multi-organ & serological activity w/ ^ immunoglobulin concentrations. Interestingly, lower lipase levels observed in males are consistent with greater degrees of pancreatic damage. https://t.co/4hUGmzTQqX @rheumnow https://t.co/kcy5dL62Pn
Dr. Rachel Tate ( View Tweet)
UTSW Dallas study: Health literacy may be essential limiting factor for families w/ children w/ SLE. Other critical barriers to patient care include food security and living costs such as transportation, housing, and utilities. #ACR23 Abs #1029 https://t.co/jtnIgLZQfC @rheumnow https://t.co/A1zr8quSdd
Dr. Rachel Tate ( View Tweet)
Cognitive function in PMR @DrTrishHarkins 71% cognitively impaired! Markedly higher than population level #ACR23 @RheumNow https://t.co/0KTnssktKz https://t.co/XyjFzioiqB
Richard Conway ( View Tweet)
@gurdeep_dulay I ask the same question always, why would you stop denosumab? Nothing comes close to fully ameliorating the negative consequences of doing so. Denosumab is for life, until we figure out how to safely get off it. Don't start it unless that is acceptable #ACR23
Richard Conway ( View Tweet)
#ACR23 #ReviewCourse - By Dr. Francesco Boin. Systemic Sclerosis Screening for Organ Involvement. This slide is a true "take home slide" @ACRheum #ACRambassador https://t.co/4FVYWJjHyV
Anne Troldborg ( View Tweet)
#Denosumab and what to do IF you stop it
#ACR23 #osteoporosis #Bisphosphonate #CTX https://t.co/qwdQQjJJlb
Dr Gurdeep S Dulay ( View Tweet)
Reduced-dose GC regimen in severe GPA or MPS (creatinine >300 umol/L, RTX as induction) associated with increased risk of death, ESKD, progression before remission requiring treatment modification or relapse, Nagle S Abst#0725 #ACR23 #ACRBest @RheumNow https://t.co/ZVZYRnSy3n
Dr. Antoni Chan ( View Tweet)
What a talk. @DrPujaMehta1 on the big stage, with a truly inspirational talk in the #ACR23 Daltroy Lecture.
If you have any thoughts at all on DEI, or just are curious, you need to watch this.
I need to listen to it again, but two initial key points for me:
@RheumNow https://t.co/G4lngvpdS7
David Liew drdavidliew ( View Tweet)
Two initial points for me:
1. Challenge how we see all this, lot of current thinking misses the mark
2. Action, not just acknowledgement, but needs to be thoughtful about what it achieves, not just reactive
I’m not doing it justice. Listen to the whole thing!
#ACR23 @RheumNow https://t.co/ydb8COnqtA
David Liew drdavidliew ( View Tweet)
Colchicine - what a fascinating medicine.
From a rheum point of view, interesting to see it play out for secondary prevention coronary artery disease, lot of patients. Great we can share our collective clinical confidence with it with cardiology
#ACR23 @US_FDA session @RheumNow https://t.co/Q7zLtyby8l
David Liew drdavidliew ( View Tweet)
PMR in the #ACR23 @US_FDA new approval update - not something you see every day!!
@RheumNow https://t.co/yll3d4AicK
David Liew drdavidliew ( View Tweet)
Clinical pearls in #CNS vasculitis: Dr. R.Hajj-Ali
🧠Clinical dx is difficult bec it presents w/ an array of clinical features
🧠CSF analysis essential in dx; can r/o infexns
🧠Nonvasc imaging highly sensitive
🧠biopsy is valuable esp when alt dx is considered
#ACR23 @RheumNow https://t.co/QOAfSHn8ND
sheila ( View Tweet)
Risk factor for 1st Thrombosis in OB APS
Ab#0115 #ACR23 @RheumNow
186 OAPS pts, followed mean 5.4 yrs. 11 thrombotic events
Risk factors: Triple pos APS Abs (OR 11.6), hypocomplementemia (OR 9)
Low dose Aspirin (OR 0.14), HCQ (OR 0.11) reduced thrombosis
#ACRBest https://t.co/y4KaEAZzA7
Eric Dein ( View Tweet)
Cowley et al @sharoncowley01 Subclinical GCA in 17.5% with new PMR. Males with higher ESR more likely to have subclinical GCA. Subclinical GCA more axillary artery. Abstr#0747 #ACR23 #ACRbest @RheumNow https://t.co/CghmX1TKpf https://t.co/MJawtslLud
Richard Conway ( View Tweet)
